NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted

The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of September 7, 2017.

GAINERS

1. NewLink Genetics Corp. (NLNK)

Gained 74.58% to close Thursday’s (Sep.7) trading at $13.60.

News: The Company reported encouraging updated data from its phase II trial of investigational drug Indoximod plus Merck & Co.’s Keytruda in advanced melanoma.

There was an improvement over previously reported results presented at the AACR Annual Meeting 2017 for both the Complete Response rate (CR) and the Overall Response Rate (ORR) for patients who received Indoximod plus Keytruda, noted the Company.

According to the updated data, Complete Response (CR) improved to 20% (10/51 patients) from the earlier reported CR of 12% (6/51 patients). The Progression-Free Survival by RECIST criteria was 56% at one year with median PFS (mPFS) of 12.9 months.

2. Verona Pharma plc (VRNA)

Gained 38.96% to close Thursday’s trading at $16.80.

News: The Company announced positive top-line results from its Phase 2a clinical trial, in which RPL554 was dosed in addition to Spiriva, one of the most commonly used drugs to treat chronic obstructive pulmonary disease.

According to the trial results, RPL554 when added to Spiriva produced significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action.

3. BioCryst Pharmaceuticals Inc. (BCRX)

Gained 20.36% to close Thursday’s trading at $5.97.

News: No news

Recent event:

On September 5, 2017, the Company announced positive results from its phase II clinical trial of BCX7353 in hereditary angioedema, dubbed APeX-1.

APeX-1 was a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of orally administered once-daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of attacks in HAE patients. This final analysis evaluated data from all patients in Parts 1, 2 and 3 of the trial.

According to the trial results, there was a 73% reduction in overall attack frequency at 125mg dose.

4. Intra-Cellular Therapies Inc. (ITCI)

Gained 16.50% to close Thursday’s trading at $22.10.

News: The Company reported positive results from its open-label safety switching study in which stable patients with schizophrenia switched to Lumateperone from standard-of-care antipsychotic therapy.

According to the trial results, statistically significant improvements from standard-of-care baseline were observed in…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *